// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Prevalence of fungal‐sensitization and response to mepolizumab in patients with severe eosinophilic asthma

Kwon N - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Impact of different definitions of atopic dermatitis on phenotyping the long‐term course of the disease

Nakamura T - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Does air pollution affect pollen concentrations through radiative feedback in the atmosphere?

Skjoth CA - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Oral corticosteroid prescription patterns in asthma care in the UK and Germany

Tran T. N - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

High‐throughput DNA sequencing defines spatiotemporal shifts in airborne grass pollen communities at species level

Griffith GW - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessing quantitative taxon‐specific grass pollen biodiversity in time and space using targeted molecular analysis of aerial environmental DNA

Brennan G - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Broad immunoglobulin G repertoire in chronic rhinosinusitis with nasal polyps regulates pro‐inflammatory IgE responses

Layhadi JA - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Intratect

Real‐life assessment of chronic rhinosinusitis patients using mobile technology

Seys SF - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Psychological factors associated with quality of life and burden in parents of children with food allergy

Sugunasingha N - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Sequential nut oral food challenges improve the quality of life of nut‐allergic children

Graham F - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Isolated orofacial clefts

N/A

Does grandmother's smoking influence asthma risk in the grandchild? A systematic review and meta‐analysis

Zhang G - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Epigenetic changes in SATB1 gene in FoxP3 + regulatory T cells reflect immune tolerance status during grass pollen subcutaneous and sublingual immunotherapy

Lenormand M - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Altered chromatin landscape in T follicular cells in seasonal allergic rhinitis and following allergen‐specific immunotherapy

Sharif H - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

N/A

Identification of nut lipid‐specific NKT receptors and their role on the intrinsic allergenicity of nut proteins

Wang R - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Extended daily dosing of AR101 for peanut allergy results in higher tolerated doses and continued immunomodulation

Blmchen K - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

High rate of sustained unresponsiveness in peanut‐allergic children undergoing oral immunotherapy using heat‐modified peanut: Results from the BOPI study

Patel N - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Identifying allergic children with severe adverse events during oral peanut challenges in the LEAP studies by assessing basophil activation

Santos AF - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Strong dose‐response using a conjunctival provocation test during a phase II allergen immunotherapy study with subcutaneously administered tyrosine adsorbed modified grass allergen + MPL

Zielen S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Immunomodulatory properties of lolium perenne peptides for the treatment of seasonal allergic rhinitis

Layhadi JA - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

histamine

A novel toll‐like receptor 7 agonist can ameliorate phleum pratense induced allergic responses in vitro

Kirtland M - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

Interferon Gamma

Copyright © 2026. QuantiNova All rights reserved